Acorda Therapeutics Announces Delisting from Nasdaq
Acorda Therapeutics Announces Nasdaq Delisting Notification
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
Tom Burns Elected to the Acorda Therapeutics Board of Directors
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
Acorda Therapeutics Reports First Quarter 2023 Financial Results
Acorda Therapeutics Reports First Quarter 2023 Financial Results
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
ESTEVE Launches INBRIJA® in Spain
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
Acorda Therapeutics to Present at Sequire Biotechnology Conference
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
Acorda Therapeutics, Inc. (ACOR) Q3 2022 Earnings Call Transcript
Acorda Therapeutics Reports Third Quarter 2022 Financial Results